Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Vitamin D supplementation helps reduce atopic dermatitis severity

01 Dec 2018

Increasing serum 25-hydroxyvitamin D (25(OH)D) levels to >20 ng/ml on top of standard therapy may yield reductions in severity of atopic dermatitis, a study has found.

A total of 65 atopic dermatitis patients were randomized to receive either vitamin D3 at 5,000 IU/day (n=33) or placebo (n=32) plus baseline therapy (topical steroid, soap substitute and emollient) for 3 months. Disease severity was assessed according to Hanifin-Rajka criteria and the severity scale (SCORAD).

Analysis included 58 patients. Serum 25(OH)D levels at the end of the intervention were significantly higher in the treated vs placebo group (p<0.001).

At week 12, patients with higher serum levels of 25(OH)D (≥20 ng/ml), regardless of whether they received supplementation, had a lower SCORAD relative to those with lower levels (<20 ng/ml; p<0.001). Furthermore, the majority (n=9; 80 percent) of patients with lower vitamin D levels had moderate–severe atopic dermatitis despite standard treatment.

Increased vitamin D levels (≥20 ng/ml) resulting from supplementation was strongly associated with remission of atopic dermatitis (p=0.03). This association persisted in patients with serum levels of ≥20 and ≥30 ng/ml.

The present data suggest that vitamin D3 be considered as a relevant adjuvant in the treatment of atopic dermatitis, researchers said. The dose administered in the cohort proved to be safe and effective for increasing 25(OH)D to levels of sufficiency in 3 months.

Additional investigation is needed to establish the cost-benefit ratio of measuring serum 25(OH)D in patients with AD, particularly those with poor response to standard treatment or with relapses, researchers added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
4 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
2 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 4 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.